Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

GABA receptor agonists and extrapyramidal motor function: therapeutic implications for Parkinson's disease.

Bartholini G, Scatton B, Zivkovic B, Lloyd KG.

Adv Neurol. 1987;45:79-83.

PMID:
3030072
2.

GABA receptor agonists: pharmacological spectrum and therapeutic actions.

Bartholini G.

Med Res Rev. 1985 Jan-Mar;5(1):55-75. Review.

PMID:
2984490
3.

Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.

Kase H, Aoyama S, Ichimura M, Ikeda K, Ishii A, Kanda T, Koga K, Koike N, Kurokawa M, Kuwana Y, Mori A, Nakamura J, Nonaka H, Ochi M, Saki M, Shimada J, Shindou T, Shiozaki S, Suzuki F, Takeda M, Yanagawa K, Richardson PJ, Jenner P, Bedard P, Borrelli E, Hauser RA, Chase TN; KW-6002 US-001 Study Group.

Neurology. 2003 Dec 9;61(11 Suppl 6):S97-100. Review.

PMID:
14663020
4.

Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.

Radad K, Gille G, Rausch WD.

Pharmacol Rep. 2005 Nov-Dec;57(6):701-12. Review.

5.

Mechanism of action of dopaminergic agents in Parkinson's disease.

Koller WC, Rueda MG.

Neurology. 1998 Jun;50(6 Suppl 6):S11-4; discussion S44-8. Review.

PMID:
9633680
6.

Peculiarities of L: -DOPA treatment of Parkinson's disease.

Kostrzewa RM, Nowak P, Kostrzewa JP, Kostrzewa RA, Brus R.

Amino Acids. 2005 Mar;28(2):157-64. Epub 2005 Mar 9. Review.

PMID:
15750845
7.

[Implications of GABAergic synapses in neuropsychiatry].

Lloyd KG, Perrault G, Zivkovic B.

J Pharmacol. 1985;16 Suppl 2:5-27. Review. French.

PMID:
2867252
8.

Multiple dopamine receptors and behavior.

Joyce JN.

Neurosci Biobehav Rev. 1983 Summer;7(2):227-56. Review.

PMID:
6136014
9.

Antiparkinsonian dopamine agonists: a review of the pharmacokinetics and neuropharmacology in animals and humans.

Wachtel H.

J Neural Transm Park Dis Dement Sect. 1991;3(3):151-201. Review.

PMID:
1683537
10.

Continuous dopamine-receptor stimulation in advanced Parkinson's disease.

Nutt JG, Obeso JA, Stocchi F.

Trends Neurosci. 2000 Oct;23(10 Suppl):S109-15. Review.

PMID:
11052228
11.

[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].

Damier P, Tremblay L, F├ęger J, Hirsch EC.

Rev Neurol (Paris). 2000 Mar;156(3):224-35. Review. French.

PMID:
10740093
12.

Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease.

Gerlach M, Double K, Reichmann H, Riederer P.

J Neural Transm Suppl. 2003;(65):167-83. Review.

PMID:
12946055
13.

Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.

Kondo T.

J Neurol. 2002 Sep;249 Suppl 2:II25-9. Review.

PMID:
12375060
14.

Pharmacology of dopamine agonists in the treatment of Parkinson's disease.

Jenner P.

Neurology. 2002 Feb 26;58(4 Suppl 1):S1-8. Review.

PMID:
11909980
15.

Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease.

Bonsi P, Cuomo D, Picconi B, Sciamanna G, Tscherter A, Tolu M, Bernardi G, Calabresi P, Pisani A.

Amino Acids. 2007 Feb;32(2):189-95. Epub 2006 May 22. Review.

PMID:
16715415
16.

Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.

Fox SH, Chuang R, Brotchie JM.

Prog Brain Res. 2008;172:479-94. doi: 10.1016/S0079-6123(08)00923-0. Review.

PMID:
18772047
17.

Physiology of the normal and dopamine-depleted basal ganglia: insights into levodopa pharmacotherapy.

Grace AA.

Mov Disord. 2008;23 Suppl 3:S560-9. doi: 10.1002/mds.22020. Review.

PMID:
18781673
18.

Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what.

Metman LV, Konitsiotis S, Chase TN.

Mov Disord. 2000 Jan;15(1):3-8. Review. No abstract available.

PMID:
10634235
19.

GABA system, GABA receptor agonists and dyskinesia.

Bartholini G.

Mod Probl Pharmacopsychiatry. 1983;21:143-54. Review. No abstract available.

PMID:
6318094

Supplemental Content

Support Center